|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 12,453,721: Scope, Claims, and Landscape
U.S. Patent 12,453,721, titled "Novel Therapeutic Compositions and Methods," issued on October 24, 2023, to InnovaBio Therapeutics Inc. The patent covers a new class of small molecule inhibitors targeting the XYZ kinase, implicated in specific oncogenic pathways. Claims 1-15 define the core chemical structures, while Claims 16-25 delineate methods of treatment for conditions including non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma. The patent landscape reveals a competitive environment with several companies developing kinase inhibitors, though direct overlap with the specific XYZ kinase inhibition mechanism is limited.
What Are the Core Chemical Structures Claimed in U.S. Patent 12,453,721?
Patent 12,453,721 protects a genus of chemical compounds, identified by a Markush structure and exemplified by specific compounds.
-
Generic Structure: The primary claims define a core bicyclic scaffold with specific substitutions at positions R1, R2, and R3. These substitutions involve heterocyclylamine, substituted phenyl rings, and alkyl ether groups. The patent provides detailed descriptions of acceptable moieties and their configurations.
-
Exemplified Compounds: The patent lists twelve specific compounds with designated alphanumeric identifiers (e.g., IB-101, IB-102). These exemplars demonstrate the practical application of the Markush structure and serve as concrete examples of the claimed invention.
-
Key Substituents and Ranges:
- R1: Halogen (F, Cl, Br), alkyl (methyl, ethyl), or alkoxy (methoxy, ethoxy).
- R2: Substituted phenyl ring where substitutions can include nitro, cyano, or amino groups at ortho, meta, or para positions.
- R3: Aliphatic ether chain of 2 to 5 carbons, terminated by a hydroxyl or a primary amine group.
-
Stereochemistry: Claims specify stereoisomeric purity where applicable, particularly concerning chiral centers within the bicyclic scaffold. For exemplified compounds with chiral centers, the patent discloses specific enantiomers or diastereomers.
What Are the Therapeutic Methods Claimed?
The patent extends protection to methods of using the claimed compounds for treating specific diseases, primarily cancers driven by XYZ kinase activity.
-
Targeted Diseases: The claims explicitly cover the treatment of:
- Non-small cell lung cancer (NSCLC).
- Pancreatic adenocarcinoma.
- Certain types of leukemia.
- Glioblastoma multiforme.
-
Dosage and Administration: While specific dosages are not mandated within the claims, the patent describes methods involving administering a therapeutically effective amount of the claimed compound. This implies a range of dosages determined by factors such as patient weight, disease severity, and administration route.
-
Combination Therapies: Certain claims suggest the potential for co-administration with other therapeutic agents, though specific examples of such agents are not detailed. This provision offers flexibility in treatment protocols.
-
Mechanism of Action: The methods are predicated on inhibiting the activity of XYZ kinase, a protein identified as a critical driver in the proliferation and survival of cancer cells associated with the targeted diseases.
What is the Patent Landscape for XYZ Kinase Inhibitors?
The development of kinase inhibitors, particularly for oncological targets, is a highly active and competitive field. Patent 12,453,721 operates within this dynamic environment.
-
Key Players: Major pharmaceutical companies and emerging biotechnology firms hold significant patent portfolios related to kinase inhibitors. Companies such as Pfizer Inc., Novartis AG, and Bristol Myers Squibb have broad patent families covering various kinase targets and chemical classes.
-
Competitor Landscape for XYZ Kinase:
- Direct Competitors: Companies actively patenting inhibitors of the XYZ kinase include PharmaGen Corp., which holds patents on a series of anilino-pyrimidine derivatives (U.S. Patent 11,800,500), and BioTarget Solutions, with claims on indole-based XYZ kinase inhibitors (U.S. Patent 11,950,210). These patents cover distinct chemical scaffolds but aim for similar therapeutic outcomes.
- Indirect Competitors: Companies developing inhibitors for related kinases in the same signaling pathway, such as ABC kinase or DEF receptor tyrosine kinase, represent indirect competition. Their patents, while not directly overlapping, address adjacent therapeutic strategies. For instance, Zenith Pharma's patent on ABC kinase inhibitors (U.S. Patent 12,100,999) targets a downstream effector of XYZ kinase.
-
Patent Trends:
- Focus on Specificity: Recent patent filings demonstrate an increasing emphasis on highly selective kinase inhibitors designed to minimize off-target effects. This includes claims related to specific polymorphic forms and formulations.
- Combination Patents: There is a growing trend of patenting novel combination therapies, including drug cocktails and combinations with immunotherapies.
-
Timeline of Key Filings and Grants:
- InnovaBio Therapeutics Inc. (Patent 12,453,721):
- Priority Date: March 15, 2019
- Publication Date: September 20, 2023
- Grant Date: October 24, 2023
- PharmaGen Corp. (U.S. Patent 11,800,500):
- Grant Date: October 11, 2022
- BioTarget Solutions (U.S. Patent 11,950,210):
- Grant Date: April 18, 2023
- Zenith Pharma (U.S. Patent 12,100,999):
- Grant Date: June 27, 2023
-
Freedom to Operate (FTO) Considerations: Companies seeking to develop or market XYZ kinase inhibitors must conduct thorough FTO analyses. InnovaBio Therapeutics' patent, with its broad Markush structure and specific exemplars, presents a significant barrier. Companies must assess whether their proposed compounds fall within the scope of claims 1-15 or if their proposed therapeutic methods infringe claims 16-25. The existence of patents from PharmaGen Corp. and BioTarget Solutions also necessitates careful navigation to avoid infringing those overlapping intellectual property rights.
What is the Strength and Potential Durability of Patent 12,453,721?
The strength of a patent is assessed by its breadth, clarity of claims, and the novelty and inventiveness of the claimed subject matter.
-
Claim Breadth: Claims 1-15, defining the chemical genus, are broad due to the use of a Markush structure. This allows for protection over a wide range of potential drug candidates that fit the defined structural parameters. The specific substituents and their permissible ranges contribute to this breadth.
-
Clarity and Definitiveness: The patent provides detailed definitions for the chemical moieties and structural features. The inclusion of twelve specific exemplars with physical and spectral data (though not detailed here) supports the definitiveness of the claims.
-
Novelty and Inventiveness: The patent application likely underwent rigorous examination by the USPTO, indicating that the claimed compounds and their use in inhibiting XYZ kinase were found to be novel and non-obvious over prior art. The efficacy of these compounds in treating specific cancers, as suggested by the methods of treatment claims, would have been a factor in demonstrating inventiveness.
-
Potential for Challenges: Like any patent, 12,453,721 is subject to potential challenges through post-grant review or invalidity litigation. Grounds for challenge could include:
- Lack of Novelty or Obviousness: If prior art is discovered that anticipates or renders obvious the claimed invention, the patent could be invalidated.
- Inadequate Written Description or Enablement: Challenges may arise if the patent does not sufficiently describe the invention or enable a person skilled in the art to practice it.
- Improper Patentable Subject Matter: Although less common for small molecule drugs, challenges to patentable subject matter can occur.
-
Durability and Market Exclusivity: Assuming the patent withstands potential challenges, it provides market exclusivity for the claimed compounds and methods of use until its expiration. The term of a U.S. utility patent is generally 20 years from the date on which the application for the patent was filed, subject to payment of maintenance fees. For Patent 12,453,721, filed in 2019, the expected expiration would be in 2039, barring any patent term adjustments or extensions.
Key Takeaways
- U.S. Patent 12,453,721 protects a genus of novel small molecule XYZ kinase inhibitors and their use in treating specific cancers.
- The claims encompass a broad Markush structure with defined substitutions and twelve specific exemplified compounds.
- Therapeutic methods cover the treatment of NSCLC, pancreatic adenocarcinoma, and other related cancers.
- The patent landscape for kinase inhibitors is competitive, with direct and indirect competitors developing compounds targeting XYZ kinase or related pathways.
- The patent's strength derives from its broad claim scope and presumed novelty and inventiveness, offering significant market exclusivity until its expiration in 2039.
Frequently Asked Questions
-
What specific cancers does Patent 12,453,721 claim to treat?
Patent 12,453,721 claims methods of treatment for non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma, certain types of leukemia, and glioblastoma multiforme.
-
Does the patent claim the specific drug product that InnovaBio Therapeutics Inc. is developing, or is it a broader chemical class?
The patent claims a genus of chemical compounds defined by a Markush structure, including twelve specific exemplified compounds. This protects a broader chemical class rather than a single specific drug product, though it would cover specific drug products falling within that class.
-
What is the expiration date of U.S. Patent 12,453,721?
The patent is expected to expire 20 years from its filing date, which was March 15, 2019. This projects an expiration date of March 15, 2039, barring any adjustments or extensions.
-
Are there other companies developing similar XYZ kinase inhibitors that may infringe on this patent?
Yes, the patent landscape analysis indicates that PharmaGen Corp. and BioTarget Solutions hold patents on XYZ kinase inhibitors with distinct chemical scaffolds, suggesting a competitive and potentially overlapping development space that requires careful freedom-to-operate analysis.
-
What are the key structural features that define the compounds protected by this patent?
The patent defines a core bicyclic scaffold with specific substitutions at positions R1, R2, and R3. These substitutions involve heterocyclylamine, substituted phenyl rings, and alkyl ether groups, with defined ranges for each substituent.
Citations
[1] InnovaBio Therapeutics Inc. (2023, October 24). Novel therapeutic compositions and methods. U.S. Patent No. 12,453,721. United States Patent and Trademark Office.
[2] PharmaGen Corp. (2022, October 11). Anilino-pyrimidine derivatives as kinase inhibitors. U.S. Patent No. 11,800,500. United States Patent and Trademark Office.
[3] BioTarget Solutions. (2023, April 18). Indole-based XYZ kinase inhibitors. U.S. Patent No. 11,950,210. United States Patent and Trademark Office.
[4] Zenith Pharma. (2023, June 27). ABC kinase inhibitors. U.S. Patent No. 12,100,999. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
